Clinical Trial Update: Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging pharmacokinetic and pharmacodynamic study of mepolizumab in asthma patients with elevated eosinophils. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2015-12-10